Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Diagnostics Raises $7M in Series B Private-Equity Round

NEW YORK, June 28 (GenomeWeb News) - Exagen Diagnostics has raised $7 million in a Series B round of private-equity financing, the company said today. 

 

Tullis-Dickerson led the round, while vSpring Capital and Wasatch Venture Fund participated. As GenomeWeb News has reported, Exagen completed a $5.7 million Series A round in early 2004 with the same group of investors.

 

Exagen, based in Albuquerque, NM, uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.

 

The company said its first test will be the Key2 Breast Cancer Prognosis panel, which is designed to detect changes in DNA copy number in both hormone receptor-positive and hormone receptor-negative tumors.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.